Spots Global Cancer Trial Database for duct cell adenocarcinoma of the pancreas
Every month we try and update this database with for duct cell adenocarcinoma of the pancreas cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | NCT01473940 | Duct Cell Adeno... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | ipilimumab gemcitabine hyd... laboratory biom... | 18 Years - | Northwestern University | |
| Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery | NCT01537107 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... Unspecified Adu... | vismodegib sirolimus positron emissi... computed tomogr... pharmacological... laboratory biom... fludeoxyglucose... | 18 Years - | Mayo Clinic | |
| Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | NCT02178436 | Acinar Cell Ade... Duct Cell Adeno... Stage IV Pancre... | gemcitabine hyd... Selinexor Pharmacological... Laboratory Biom... Nab paclitaxel | 19 Years - | Barbara Ann Karmanos Cancer Institute | |
| Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer | NCT02048943 | Duct Cell Adeno... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... Unspecified Adu... | dovitinib lacta... gemcitabine hyd... paclitaxel albu... pharmacological... laboratory biom... | 18 Years - | Roswell Park Cancer Institute | |
| MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery | NCT01098344 | Pancreatic Canc... | Notch signaling... gemcitabine hyd... imaging biomark... laboratory biom... pharmacological... | 18 Years - | Cancer Research UK | |
| Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine | NCT00397787 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer | NCT00058201 | Pancreatic Canc... | fluorouracil gemcitabine hyd... leucovorin calc... clinical observ... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer | NCT01473303 | Pancreatic Canc... | ganitumab fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin placebo questionnaire a... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | NCT01234935 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... | dasatinib gemcitabine hyd... laboratory biom... mutation analys... nucleic acid se... immunohistochem... | 18 Years - | Translational Oncology Research International | |
| Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | NCT01643499 | Acinar Cell Ade... Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Diffuse Adenoca... Duct Cell Adeno... Intestinal Aden... Localized Unres... Metastatic Carc... Metastatic Extr... Mixed Adenocarc... Mucinous Adenoc... Mucinous Adenoc... Newly Diagnosed... Signet Ring Ade... Signet Ring Ade... Stage III Pancr... Stage IIIA Colo... Stage IIIA Gall... Stage IIIA Gast... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Gall... Stage IIIB Gast... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Rect... Stage IV Gastri... Stage IV Pancre... Stage IVA Colon... Stage IVA Gallb... Stage IVA Recta... Stage IVB Colon... Stage IVB Gallb... Stage IVB Recta... Unresectable Ex... | oxaliplatin irinotecan hydr... leucovorin calc... fluorouracil laboratory biom... | 18 Years - | University of Chicago | |
| Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | NCT01666730 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... | metformin hydro... oxaliplatin leucovorin calc... fluorouracil laboratory biom... | 18 Years - | Case Comprehensive Cancer Center | |
| Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride | NCT00981162 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... Unspecified Adu... | sorafenib tosyl... everolimus laboratory biom... pharmacogenomic... pharmacological... | 18 Years - | Roswell Park Cancer Institute | |
| Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | NCT01666730 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... | metformin hydro... oxaliplatin leucovorin calc... fluorouracil laboratory biom... | 18 Years - | Case Comprehensive Cancer Center | |
| Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer | NCT02048943 | Duct Cell Adeno... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... Unspecified Adu... | dovitinib lacta... gemcitabine hyd... paclitaxel albu... pharmacological... laboratory biom... | 18 Years - | Roswell Park Cancer Institute | |
| Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer | NCT00052689 | Duct Cell Adeno... Stage IV Pancre... | bortezomib gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | NCT01234935 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... | dasatinib gemcitabine hyd... laboratory biom... mutation analys... nucleic acid se... immunohistochem... | 18 Years - | Translational Oncology Research International | |
| Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT00425360 | Pancreatic Canc... | sargramostim telomerase pept... capecitabine gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer | NCT01666730 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... | metformin hydro... oxaliplatin leucovorin calc... fluorouracil laboratory biom... | 18 Years - | Case Comprehensive Cancer Center | |
| Vaccine Therapy Combined With Adjuvant Chemoradiotherapy in Treating Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas | NCT00084383 | Pancreatic Canc... | GVAX pancreatic... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer | NCT00058201 | Pancreatic Canc... | fluorouracil gemcitabine hyd... leucovorin calc... clinical observ... | 18 Years - | National Cancer Institute (NCI) | |
| Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung | NCT01741597 | Acinar Cell Ade... Duct Cell Adeno... Liver Metastase... Lung Metastases Recurrent Breas... Recurrent Pancr... Stage IV Breast... Stage IV Pancre... | dynamic contras... pharmacological... tumor-homing pe... | 18 Years - | City of Hope Medical Center | |
| Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer | NCT00031694 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | paclitaxel bryostatin 1 | 19 Years - | National Cancer Institute (NCI) | |
| Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer | NCT00550836 | Pancreatic Canc... | panitumumab erlotinib hydro... gemcitabine hyd... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer | NCT00305760 | Pancreatic Canc... | Cetuximab Pancreatic tumo... Cyclophosphamid... | 18 Years - 120 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery | NCT01473940 | Duct Cell Adeno... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | ipilimumab gemcitabine hyd... laboratory biom... | 18 Years - | Northwestern University | |
| DX-8951f in Treating Patients With Metastatic Cancer of the Pancreas | NCT00003951 | Pancreatic Canc... | exatecan mesyla... | 18 Years - | Daiichi Sankyo | |
| Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer | NCT00112528 | Pancreatic Canc... | bevacizumab gemcitabine hyd... oxaliplatin | 18 Years - | Alliance for Clinical Trials in Oncology | |
| S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer | NCT00003018 | Pancreatic Canc... | dipyridamole fluorouracil leucovorin calc... mitomycin C | 18 Years - | SWOG Cancer Research Network | |
| Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer | NCT01770132 | Acinar Cell Ade... Duct Cell Adeno... Stage III Pancr... | porfimer sodium endoscopic ultr... photodynamic th... gemcitabine hyd... | 18 Years - 60 Years | Indiana University | |
| Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer | NCT01473303 | Pancreatic Canc... | ganitumab fluorouracil irinotecan hydr... leucovorin calc... oxaliplatin placebo questionnaire a... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery | NCT01739439 | Acinar Cell Ade... Duct Cell Adeno... Stage IIB Pancr... Stage III Pancr... | gemcitabine hyd... hyperfractionat... intensity-modul... radiosurgery diffusion-weigh... | 18 Years - | Fox Chase Cancer Center | |
| Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine | NCT00397787 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IV Pancre... | sunitinib malat... | 18 Years - | National Cancer Institute (NCI) | |
| Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery | NCT01234935 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... | dasatinib gemcitabine hyd... laboratory biom... mutation analys... nucleic acid se... immunohistochem... | 18 Years - | Translational Oncology Research International | |
| Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer | NCT00550836 | Pancreatic Canc... | panitumumab erlotinib hydro... gemcitabine hyd... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT00005832 | Pancreatic Canc... | R115777 | 18 Years - | SWOG Cancer Research Network | |
| Gemcitabine Hydrochloride in Treating Patients With Locally Advanced Pancreatic Cancer | NCT01893294 | Duct Cell Adeno... Stage III Pancr... Stage IV Pancre... | gemcitabine hyd... fluorouracil radiation thera... laboratory biom... | 18 Years - | Mayo Clinic | |
| Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery | NCT01739439 | Acinar Cell Ade... Duct Cell Adeno... Stage IIB Pancr... Stage III Pancr... | gemcitabine hyd... hyperfractionat... intensity-modul... radiosurgery diffusion-weigh... | 18 Years - | Fox Chase Cancer Center | |
| Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies | NCT01643499 | Acinar Cell Ade... Adenocarcinoma ... Adenocarcinoma ... Adult Primary C... Advanced Adult ... Cholangiocarcin... Cholangiocarcin... Diffuse Adenoca... Duct Cell Adeno... Intestinal Aden... Localized Unres... Metastatic Carc... Metastatic Extr... Mixed Adenocarc... Mucinous Adenoc... Mucinous Adenoc... Newly Diagnosed... Signet Ring Ade... Signet Ring Ade... Stage III Pancr... Stage IIIA Colo... Stage IIIA Gall... Stage IIIA Gast... Stage IIIA Rect... Stage IIIB Colo... Stage IIIB Gall... Stage IIIB Gast... Stage IIIB Rect... Stage IIIC Colo... Stage IIIC Gast... Stage IIIC Rect... Stage IV Gastri... Stage IV Pancre... Stage IVA Colon... Stage IVA Gallb... Stage IVA Recta... Stage IVB Colon... Stage IVB Gallb... Stage IVB Recta... Unresectable Ex... | oxaliplatin irinotecan hydr... leucovorin calc... fluorouracil laboratory biom... | 18 Years - | University of Chicago | |
| Gene Therapy in Treating Patients With Cancer | NCT00004178 | Cancer | therapeutic aut... | 18 Years - | Roger Williams Medical Center | |
| Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer | NCT00033735 | Pancreatic Canc... | fluorouracil Irofulven | 18 Years - | Eisai Inc. | |
| CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer | NCT00033384 | Breast Cancer Colorectal Canc... Lung Cancer Pancreatic Canc... | CI-1040 | 18 Years - | University of Alabama at Birmingham | |
| Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer | NCT00052689 | Duct Cell Adeno... Stage IV Pancre... | bortezomib gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer | NCT00004190 | Pancreatic Canc... | gemcitabine hyd... oxaliplatin | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer | NCT00416793 | Acinar Cell Ade... Duct Cell Adeno... Stage IV Pancre... | bortezomib carboplatin laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer | NCT00033735 | Pancreatic Canc... | fluorouracil Irofulven | 18 Years - | Eisai Inc. | |
| Bevacizumab, Gemcitabine, and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer | NCT00112528 | Pancreatic Canc... | bevacizumab gemcitabine hyd... oxaliplatin | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer | NCT02047474 | Acinar Cell Ade... Duct Cell Adeno... Stage I Pancrea... Stage IIA Pancr... Stage IIB Pancr... | oxaliplatin leucovorin calc... irinotecan hydr... fluorouracil therapeutic con... laboratory biom... | 18 Years - | Yale University | |
| Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT00032175 | Pancreatic Canc... | capecitabine gemcitabine hyd... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas | NCT00006467 | Pancreatic Canc... | ISIS 2503 gemcitabine hyd... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT01839981 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | 6,8-bis(benzylt... | 18 Years - | Wake Forest University Health Sciences | |
| Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer | NCT00058201 | Pancreatic Canc... | fluorouracil gemcitabine hyd... leucovorin calc... clinical observ... | 18 Years - | National Cancer Institute (NCI) | |
| MK0752 and Gemcitabine Hydrochloride in Treating Patients With Stage III and IV Pancreatic Cancer That Cannot Be Removed by Surgery | NCT01098344 | Pancreatic Canc... | Notch signaling... gemcitabine hyd... imaging biomark... laboratory biom... pharmacological... | 18 Years - | Cancer Research UK | |
| CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT01839981 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | 6,8-bis(benzylt... | 18 Years - | Wake Forest University Health Sciences | |
| Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer | NCT02178436 | Acinar Cell Ade... Duct Cell Adeno... Stage IV Pancre... | gemcitabine hyd... Selinexor Pharmacological... Laboratory Biom... Nab paclitaxel | 19 Years - | Barbara Ann Karmanos Cancer Institute | |
| Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas | NCT00085371 | Acinar Cell Ade... Duct Cell Adeno... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... | triapine | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
